Moleculin Biotech has inked an agreement with the University of Campinas in São Paulo, Brazil, to collaborate on researching the antiviral capabilities of WP1122, its COVID-19 drug candidate.
Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in the first half of 2021, pending licensure in Japan, as part of a three-way agreement with Takeda, Moderna, and the government of Japan.
Emulate has entered a cooperative research and development agreement with the U.S. Food and Drug Administration (FDA) to enable multiple studies to evaluate COVID-19 vaccines and understand immune responses against SARS-CoV-2.
The U.S. Food and Drug Administration has provided written feedback to Qualigen Therapeutics on the company's plan to advance its COVID-19 DNA aptamer drug candidate to clinical trials.
Eli Lilly has entered an initial agreement with the U.S. government to supply 300,000 vials of LY-CoV555 (bamlanivimab), the company's investigational neutralizing antibody to fight SARS-CoV-2 infection, for $375 million.
The Global Coalition for Adaptive Research (GCAR) said that the first patient has been enrolled in an adaptive multicenter clinical trial to test interventions for hospitalized COVID-19 patients.
Nektar Therapeutics has received clearance from the U.S. Food and Drug Administration for an investigational new drug application for its interleukin-2 pathway agent NKTR-214 (Bempegaldesleukin) for evaluation in a phase IB clinical study in adult patients with mild COVID-19 infection.
A new assay that detects the unique SARS-CoV-2 orf8 protein in the sera of COVID-19 patients in the early stage of the infection is a strategic step in controlling the COVID-19 pandemic, according to research published online October 20 in mBio. Discuss
Once a vaccine for SARS-CoV-2 is approved by the U.S. Food and Drug Administration to be administered to the public, who should receive it first, given that its supply will be initially limited? A new perspective published in Science on October 21 fleshes out different COVID-19 vaccine distribution strategies that would ensure optimal protection from the disease under conditions of vaccine scarcity. Discuss
HiFiBiO Therapeutics has completed the first cohort of a phase I clinical study evaluating a SARS-CoV-2 neutralizing antibody.
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
